Company intelligence / Profile preview
Neuvivo
Palo Alto, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Neuvivo’s lead candidate, NP001, has completed Phase 2a and Phase 2b studies and an overall survival study. The company submitted an NDA to the FDA in October 2024. Clinical data suggest that NP001 may preserve lung function and extend survival by up to a year in biomarker-selected ALS patients with underlying inflammation. The drug has Orphan Drug and Fast Track designation from the FDA.
- Therapeutic areas
- Neurology
- Modalities
- Small moleculeInfusion therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
None publicly disclosed; no major pharma/biotech partnerships listed as of June 2025.
Beyond the preview
Go deeper on Neuvivo.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuvivo.